Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Streamlining cell therapy manufacturing with CliniMACS Prodigy

Saskia Rösch • 6 Apr 2022
ICLE 2022
General

Saskia Rösch, PhD, Miltenyi Biotec, Bergisch Gladbach, Germany, gives an overview of CliniMACS Prodigy, a novel next-generation automated cell processing platform that aims to separate and process cell cultures for the manufacturing of cell therapies. The closed, scalable system enables the production of good manufacturing practice (GMP) compliant products of consistent quality in a safe and clean environment. CliniMACS Prodigy additionally is flexible in a centralized or decentralized setting and can be used for various cell types including induced pluripotent stem (iPS) cells, chimeric antigen receptor (CAR) T-cells and natural killer (NK) cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

More from Saskia Rösch

1:28
Implementing automation technology in the CGT space
Saskia Rösch • 6 Apr 2022
3:10
Utilizing flow cytometry in CAR T-cell research
Saskia Rösch • 6 Apr 2022
4:06
Optimizing the upscaling and outscaling of CAR T-cell therapies
Saskia Rösch • 6 Apr 2022
1:27
Direct detection and isolation of CAR cells from patient samples
Saskia Rösch • 6 Apr 2022

Related Videos

0:55
Multivalent gamma-delta T-cells: promising agents for the treatment of cancers
Jürgen Kuball • 10 Feb 2023
1:26
Rapid CAR-T manufacturing and challenges in this space
Nina Worel • 9 Feb 2023
1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri • 9 Feb 2023
1:28
Implementing automation technology in the CGT space
Saskia Rösch • 6 Apr 2022
The content of VJRegenMed is intended for healthcare professionals